title: [The modified program NHL-BFM-90 in the treatment of patients with diffuse large B-cell lymphosarcoma].
abstract: OBJECTIVE
  To investigate efficacy of the modified protocol NHL-BFM-90 in patients with diffuse large B-cell lymphosarcoma (DLBCLS).
  
  
  METHODS
  A total of 13 DLBCLS patients with stage II-IV of the disease with affection of lymph nodes at the disease onset (nodal lesion) and stage II with tumor size more than 10 cm (bulky disease) received first-line treatment according to the modified program NHL-BFM-90 from 2002 to 2005. The diagnosis was made by WHO criteria.
  
  
  RESULTS
  A complete remission was achieved in 76.9% patients. Resistance to therapy was observed in the patients with bone marrow affection. The 2.5-year overall survival was 74%, 2-year event-free survival was 75% (the events were recurrence and resistance). Follow-up continued from 5 to 47 months.
  
  
  CONCLUSIONS
  The efficacy of the modified protocol NHL-BFM-90 in DLBCLS patients with stage III-IV of the "nodal" disease and stage II of the "bulky" disease was high.
authors.forename: A U
authors.initials: AU
authors.lastname: Magomedova
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
authors.forename: A M
authors.initials: AM
authors.lastname: Kremenetskaia
authors.forename: E E
authors.initials: EE
authors.lastname: Zvonkov
authors.forename: E A
authors.initials: EA
authors.lastname: Bariakh
authors.forename: O V
authors.initials: OV
authors.lastname: Margolin
authors.forename: I B
authors.initials: IB
authors.lastname: Kaplanskaia
authors.forename: I A
authors.initials: IA
authors.lastname: Vorob'ev
authors.forename: R S
authors.initials: RS
authors.lastname: Samoĭlova
authors.forename: T N
authors.initials: TN
authors.lastname: Obukhova
authors.forename: T N
authors.initials: TN
authors.lastname: Moiseeva
authors.forename: E E
authors.initials: EE
authors.lastname: Zybunova
authors.forename: E G
authors.initials: EG
authors.lastname: Gemdzhian
authors.forename: A I
authors.initials: AI
authors.lastname: Vorob'ev
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015996:Survival Rate